Advertisement
Skip to Content

HLS Therapeutics Inc HLTRF Stock Quote

| Rating as of

PINX: HLTRF

Last close prices updated as of Jan 31, 2023, 1:21 PM EST | USD
  • Last Close 7.15
  • Sector Healthcare
  • Industry Drug Manufacturers - Specialty & Generic
  • Investment Style Small Value
  • Day Range 7.14  –  7.15
  • Year Range 6.20  –  12.01
  • Market Cap 231.5422 Mil
  • Volume / Avg 1,500.0 /  12,929.5
  • Price / Sales 3.77
  • Price / Book 1.76
  • Forward Div Yield 2.09%
  • Trailing Div Yield 2.80%

Morningstar‘s Stock Analysis HLTRF

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics HLTRF

Company Profile HLTRF

Business Description

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.

Contact
10 Carlson Court, Suite 701
Etobicoke, ON, M9W6L2, CAN
Industry Drug Manufacturers - Specialty & Generic
Employees 94

FAQs for HLS Therapeutics Inc Stock

Yes. HLTRF has a forward dividend yield of 2.09%. See HLTRF’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

HLTRF’s market cap is 231.54 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

HLTRF’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

HLTRF’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare HLTRF’s historical performance against its industry peers and the overall market.